Genmab — Januar 2019
-
...hvordan er det med sc H1 19 - det er RRMM setting. Vil studiet kunne bruges pivotalt i første linie også?
-
Man mener, at sc-dara vil kunne konverteres til alle godkendte linier - hvis forsøget falder godt ud. Jeg er ikke så meget i tvivl om effekt og sideeffekt. Kun at dara konc i blod ser ud til at være en streg højere end i 16 mg settings kan give problemer - men næppe relevant hvis sideeffects og effekt begge går i rigtig retning.
-
...er det NCT03412565 (fase2), der er det pivotale i 1st line SC? Den har primary completion I Q3 19
-
indeholder 199 patienter
-
ok - så vi har en horisont på lige nord for 12 måneder for SC I alle linier
-
Q&A Feb18 - Q: In january you started a “Study to evaluate Subcutaneous Daratumumab in
combination with Standard Multiple Myeloma Treatment Regimens”, which is a Phase
2. You already have the Phase 3 SC vs IV study; could these 2 clinical trials be the
basis for an overall approval of SC in all lines and settings?
Jan : This is a good thought. -
I´ve never understood why split dosing is such a great improvement. You have to take same dosis over 2 days. Same patient must be at the hospital twice as many times and be cleared for treatment. You have to do all the manuel procedures twice against a small time gain ?
-
Mon der er warrants ude? Danske største nettosælger.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind